Please login to the form below
non-Hodgkin's lymphoma
This page shows the latest non-Hodgkin's lymphoma news and features for those working in and with pharma, biotech and healthcare.
Regeneron’s odronextamab granted FDA priority review for non-Hodgkin lymphoma
FL and DLBCL represent the two most common subtypes of B-cell non-Hodgkin lymphoma. ... cell lymphoma, marginal zone lymphoma and other subtypes of B-cell non-Hodgkin lymphoma.
Latest news
-
Roche's fixed-duration lymphoma treatment approved by European Commission
Roche's fixed-duration bispecific antibody Columvi (glofitamab) has been granted conditional marketing authorisation by the European Commission (EC) to treat adults with an aggressive form of lymphoma. ... Each year in Europe, an estimated 36, 000 people
-
Roche's fixed-duration lymphoma treatment granted FDA accelerated approval
Globally around 160, 000 people are diagnosed with non-Hodgkin's lymphoma each year. ... Around 160, 000 people worldwide are estimated to be diagnosed each year with DLBCL – the most common form of non-Hodgkin's lymphoma.
-
Janssen signs $245m deal with Cellular Biomedicine for pair of CAR T-cell therapies
The candidates have shown the potential to treat forms of non-Hodgkin’s lymphoma. ... The investigational CAR-Ts have shown promising early-stage results in patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL), the companies said, with the
-
BeiGene’s Brukinsa receives EC approval for marginal zone lymphoma
BeiGene’s Brukinsa (zanubrutinib) has been approved by the European Commission (EC) for the treatment of adult patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who have received at ... BTK inhibitor for marginal zone lymphoma in
-
AbbVie submits application for lymphoma therapy epcoritamab to EMA
of investigational epcoritamab in adult patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin's lymphoma (NHL), including DLBCL. ... large B-cell lymphoma and diffuse large B-cell lymphoma who have limited treatment options.
More from news
Approximately 18 fully matching, plus 133 partially matching documents found.
Latest Intelligence
-
Pharma deals during October 2014
Zykadia is approved in the US for patients with anaplastic lymphoma kinase (ALK) and metastatic NSCLC but not approved elsewhere; INC 280 and EFG 816 are in phase 1 development; the ... Hodgkin's lymphoma.
-
Interview: Kay Drake and Naoki Okamura, Astellas
The company has also out-licensed a non-small cell lung cancer treatment (Tarceva) and non-Hodgkin's lymphoma treatment (bendamustine) to its strategic partners, with several prospective new oncology medications ... So that's where we need the diversity,
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Charles Morris appointed chief development officer at ImmunoGen
Previously worked in oncology for Allos, Cephalon and AstraZeneca. Immunogen has appointed Dr Charles Morris as the company's chief development officer. ... cancers that over-express folate receptor 1, and IMGN529 - in phase I testing for the treatment
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Therapy Watch expands oncology and IBD portfolios
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer
-
Therapy Watch expands its oncology portfolio
Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal
-
Oncology drugs under AMNOG
Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’s B-cell lymphoma, on the basis of a trial ... against ‘treatment of physician’s
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Sanofi and Teva to collaborate on inflammatory bowel disease drug in deal worth $1.5bn
- Eli Lilly to acquire cancer specialist Point Biopharma in deal worth $1.4bn
- Regeneron and Intellia to develop additional gene editing therapies under expanded collaboration
- Novavax’s updated COVID-19 vaccine approved by FDA for emergency use
- Alzheimer’s Research UK awards Cardiff University researchers £387,000
- Actinic keratosis – a common skin condition that can lead to skin cancer
No results were found
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....
Latest intelligence
- Actinic keratosis – a common skin condition that can lead to skin cancer
- PMGroup talks to Volker Koscielny, Chief Medical Officer at Almirall, about the importance of remaining vigilant about skin checks, the prevalence of actinic keratosis in the UK and the steps...
- Man vs microbe: the fight against antimicrobial resistance
- How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
- Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
- Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...
